May 2 |
Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024
|
May 1 |
Lisata Therapeutics files for $150M mixed securities shelf
|
Apr 23 |
Lisata Therapeutics advances lead asset LSTA1 for treatment of advanced solid tumors
|
Apr 23 |
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
|
Apr 10 |
Lisata's (LSTA) LSTA1 Gets FDA Orphan Drug Tag for Osteosarcoma
|
Apr 9 |
Lisata Therapeutics receives FDA orphan drug designation granted to its osteosarcoma treatment
|
Apr 9 |
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma
|
Mar 21 |
Lisata gets FDA rare pediatric disease status for lead drug
|
Mar 21 |
Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma
|
Mar 15 |
Here's Why We're Watching Lisata Therapeutics' (NASDAQ:LSTA) Cash Burn Situation
|